Clinical Trials Browser

Recurrence, Lymphoma, T-Cell, Lymphoma, T-Cell, Cutaneous, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma

NCT07529405 2026-04-14

CurbMF

Phase 2 Not yet recruiting

386 enrolled

Lymphoid

Mycosis Fungoides

NCT06698003 2026-03-05

A Study of Mogamulizumab to Prevent Adult T-cell Leukemia/Lymphoma in People With HTLV-1

Phase 2 Recruiting

134 enrolled

LymphoidOther hematologic neoplasm

Lymphoma, Leukemia, T-Cell, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma

NCT05956041 2026-01-07

Pembrolizumab and Mogamulizumab in Advanced-stage, Relapsed/Refractory Cutaneous T-cell Lymphomas

Phase 2 Recruiting

23 enrolled

DermatologicLymphoid

Lymphoma, T-Cell, Cutaneous

NCT04930653 2025-10-14

Extracorporeal Photopheresis and Mogamulizumab for the Treatment of Erythrodermic Cutaneous T Cell Lymphoma

Phase 2 Recruiting

34 enrolled

DermatologicLymphoid

Mycosis Fungoides, Sezary Syndrome, Lymphoma, T-Cell, Cutaneous

NCT04256018 2025-07-02

Mogamulizumab + Low-Dose Total Skin Electron Beam Tx in Mycosis Fungoides & Sézary Syndrome

Phase 2 Recruiting

30 enrolled

Lymphoid

Mycosis Fungoides, Sezary Syndrome

NCT01611142 2024-06-17

Study of KW-0761 (Mogamulizumab) in Subjects With Previously Treated Peripheral T-cell Lymphoma (PTCL)

Phase 2 Completed

38 enrolled

LymphoidOther hematologic neoplasm

Neoplasms, Lymphoma, T-Cell, Peripheral, Hematologic Neoplasms

NCT01226472 2024-04-25

Extension Study in Subjects Who Relapsed After Complete Response on Study KW-0761-001

Phase 2 Completed

1 enrolled 5 charts

DermatologicLymphoid

Lymphoma, T-Cell, Cutaneous, Lymphoma, T-Cell, Peripheral

NCT01626664 2024-04-25

KW-0761 or Investigator's Choice in Subjects With Previously Treated Adult T-cell Leukemia-Lymphoma (ATL)

Phase 2 Completed

71 enrolled 15 charts

LymphoidOther hematologic neoplasm

Leukemia-Lymphoma, Adult T-Cell, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma

NCT04745234 2024-04-25

Mogamulizumab Q4week Dosing in Participants With R/R CTCL

Phase 2 Active not recruiting

34 enrolled

DermatologicLymphoid

Recurrence, Lymphoma, T-Cell, Cutaneous

NCT04128072 2024-04-05

MOGAT

Phase 2 Recruiting

43 enrolled

DermatologicLymphoid

Lymphoma, T-Cell, Cutaneous

NCT01173887 2017-03-30

Multicenter, Randomized, Open-label, Parallel-group Study to Compare mLSG15 + KW-0761 to mLSG15

Phase 2 Completed

44 enrolled

LymphoidOther hematologic neoplasm

Leukemia-Lymphoma, Adult T-Cell

NCT00920790 2017-03-29

Phase II Study of KW-0761 in Subjects With CCR4-positive Adult T-cell Leukemia-lymphoma

Phase 2 Completed

28 enrolled 10 charts

LymphoidOther hematologic neoplasm

Leukemia-Lymphoma, Adult T-Cell

Clinical Trials

Study of Mogamulizumab With DA-EPOCH or CHOEP in Patients With Aggressive T-cell Lymphoma

CurbMF

A Study of Mogamulizumab to Prevent Adult T-cell Leukemia/Lymphoma in People With HTLV-1

Pembrolizumab and Mogamulizumab in Advanced-stage, Relapsed/Refractory Cutaneous T-cell Lymphomas

Extracorporeal Photopheresis and Mogamulizumab for the Treatment of Erythrodermic Cutaneous T Cell Lymphoma

Mogamulizumab + Low-Dose Total Skin Electron Beam Tx in Mycosis Fungoides & Sézary Syndrome

Study of KW-0761 (Mogamulizumab) in Subjects With Previously Treated Peripheral T-cell Lymphoma (PTCL)

Extension Study in Subjects Who Relapsed After Complete Response on Study KW-0761-001

KW-0761 or Investigator's Choice in Subjects With Previously Treated Adult T-cell Leukemia-Lymphoma (ATL)

Mogamulizumab Q4week Dosing in Participants With R/R CTCL

MOGAT

Multicenter, Randomized, Open-label, Parallel-group Study to Compare mLSG15 + KW-0761 to mLSG15

Phase II Study of KW-0761 in Subjects With CCR4-positive Adult T-cell Leukemia-lymphoma